Navigation Links
Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
Date:7/1/2009

s; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; (xiii) our ability to successfully integrate the business of Remedium OY, which we acquired on November 1, 2006; (xiv) the performance of the combined businesses to operate successfully and generate growth; and (xv) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Form 10-K for a more complete discussion of factors which could cause our actual results and financial position to change.

You should not place any undue reliance on these forward-looking statements which speak only as of the date of this press release. Additional information concerning factors that might affect our business or stock price which could cause actual results to materially differ from those in forward-looking statements is contained in Encorium Group's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2008 and other periodic reports under the Securities Exchange Act of 1934, as amended, copies of which are available upon request from Encorium Group's investor relations department.

www.encorium.com


'/>"/>
SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Avicena Group to Present at Noble Financial Conference
9. Chrome Group to Seek Listing for Some of its Subsidiaries
10. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
11. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Costello served ... levee system to protect the Orange County, Texas area from future storm surge ... design team in determining several potential levee alignment alternatives for providing protection, Costello also ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Nearly everyone ... serious diseases. Yet few people realize that a rich source of these cells is ... adults, and teeth that need to be pulled to make room for braces. ...
(Date:7/28/2015)... ... 2015 , ... The new Xsample 530 sample changer for vials can be used ... viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external air) – ... catches the eye about Xsample 530 is its removable magazine, which is easily lifted off ...
(Date:7/28/2015)... Seahorse Bioscience, the industry leader in ... of XF Technology which is increasingly being adopted ... the links between mitochondrial function and disease are ... rapidly.   Recently, 12 peer-reviewed publications ... (NPG) featuring XF Technology, including Nature, Nature Genetics, ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2New Moves in Automatic Sample Handling: Introducing Xsample 530 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3
... , , ... AB (publ),and BioChromix AB announced today the formation of BioChromix Pharma ... its unique,knowledge of molecular chemistry. Karolinska Development will initially take,28 percent ... are very excited about BioChromix Pharma as they have a novel,approach ...
... , ... supports Higher Education and Local Youth by establishing Five College Scholarships. The first ... pursue Bio-Technology studies at NoVA. The company will also sponsor four scholarships for ... ...
... Jan. 13 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... the introduction of new products during a presentation today at the ... the brief presentation, limited by conference organizers to 10 minutes per ... in its cosmetics line during 2010. They include an eye cream ...
Cached Biology Technology:Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 2Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 3RiVIdium Inc. Creates Five Local Scholarships 2Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation 2Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... on the Cohen Y chromosome indicates the Jewish priesthood, the ... a single male lineage dating to ancient Hebrew times. ... Jewish priesthood that traced its patrilineal dynasty and seemed to ... (and brother of Moses), was one of a number of ...
... A scientist at the La Jolla Institute for Allergy & ... (NIH),s top awards -- the 2009 NIH Director,s Pioneer Award. ... costs of up to $4.7 million over five years, and ... whose novel proposals offer the potential to make extraordinary contributions ...
... RICHLAND, Wash. -- An analytical chemist at the Department ... with a National Institutes of Health Director,s New Innovator ... make new research and clinical diagnostic tools that are ... The award, which comes with a $1.5 million, ...
Cached Biology News:New genetic research indicates Jewish priesthood has multiple lineages 2Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 2Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 3Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 4PNNL chemist earns NIH New Innovator Award 2PNNL chemist earns NIH New Innovator Award 3
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
... (Ser385) Immunogen: ... acid region encompassing the human, ... Accession Number: ... Quality Assurance: Routinely evaluated ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
TNR-R2...
Biology Products: